Table 2. Univariate analysis of SIRT3 expression and clinicopathologic variables in 248 patients with primary hepatocellular carcinoma (log-rank test).

Variable	All cases	Overall survival (months)			Recurrence-free survival (months)
		Mean	Median	P value	Mean	Median	P value
Age (years)a				0.963			0.997
<47.8	130	49.0	38.0		42.8	29.0
≥47.8	118	48.8	40.0		43.8	38.0
Gender				0.359			0.641
Female	28	52.5	NR		34.6	35.0
Male	220	48.5	38.0		44.6	42.0
HBsAg				0.722			0.298
Positive	215	49.5	38.0		43.1	32.0
Negative	33	44.8	38.0		47.9	42.0
AFP (ng/ml)				0.000			0.000
<20	102	65.8	NR		52.9	57.0
≥20	146	37.7	27.0		36.1	25.0
Cirrhosis				0.500			0.529
Yes	180	48.2	36.0		42.1	30.0
No	68	51.7	NR		47.6	42.0
Tumor size (cm)				0.000			0.000
<5	121	59.1	NR		53.4	74.0
≥5	127	40.8	27.0		35.3	22.0
Tumor multiplicity				0.000			0.008
Single	131	62.6	NR		49.8	42.0
Multiple	117	35.3	24.0		36.7	26.0
Differentiation				0.003			0.024
Well-Moderate	150	54.6	NR		47.7	42.0
Poor- Undifferentiation	98	41.0	26.0		36.4	26.0
Stage				0.000			0.000
I–II	109	70.9	NR		61.7	NR
III–IV	139	33.4	21.0		31.0	22.0
Vascular invasion				0.000			0.000
Yes	73	26.8	18.0		18.5	15.0
No	175	58.2	NR		57.9	NR
Relapse				0.000
Yes	101	31.1	24.0
No	147	64.2	NR
SIRT3				0.000			0.004
Low expression	167	40.9	28.0		37.4	28.0
High expression	81	65.0	NR		53.5	NR

^aMean age;

NR, not reached; HbsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein.